Positive modulators of AMPA receptors as a potential treatment for schizophrenia

Current Opinion in Investigational Drugs

Volumn 3, Issue 7, 2002, Pages 1062-1066

  Danysz, Wojciech ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

AMPA; Glutamate; Schizophrenia

Indexed keywords

1 (1,3 BENZODIOXOL 5 YL CARBONYL)PIPERIDINE; 2,3 DIHYDRO 3,4 CYCLOPENTANO 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; 4 METHYL 4,5 DIHYDRO 1,3 DITHIA 4 AZAACENAPHTHYLENE 3,3 DIOXIDE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; 7 BROMO 4 ETHYL 2,3 DIHYDRO 4H 1,2,4, BENZOTHIADIAZINE 1,1 DIOXIDE; 7 CHLORO 3,4 DIHYDRO 3 METHYL 2H 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; AMPA RECEPTOR; AMPA RECEPTOR POSITIVE MODULATOR; AMPHETAMINE; ANIRACETAM; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CX 546; CX 614; CYCLOTHIAZIDE; DIZOCILPINE; FLUPHENAZINE; GLUTAMIC ACID; HALOPERIDOL; KETAMINE; LY 392098; LY 404187; METHAMPHETAMINE; NEUROLEPTIC AGENT; NS 1209; OLANZAPINE; PHENCYCLIDINE; RISPERIDONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADD ON THERAPY; BEHAVIOR; BEHAVIOR DISORDER; BIOCHEMISTRY; CATALEPSY; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG INDICATION; DRUG INHIBITION; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOXICITY; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LEARNING; NEGATIVE SYNDROME; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TRANQUILIZING ACTIVITY;

ANIMALS; CLINICAL TRIALS; DIOXOLES; DRUG INDUSTRY; EXCITATORY AMINO ACID AGONISTS; HUMANS; PIPERIDINES; RECEPTORS, AMPA; SCHIZOPHRENIA;

EID: 0036667103     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Lieberman JA, Alvir JM, Woener M, Degreef G, Bilder RM, Ashtari M, Bogerts B, Mayerhoff DI, Geisler SH, Loebel A et al: Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. Schizophrenia Bull (1992) 18:351-371.
2. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Charney DS: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans - Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 51:199-214.
3. Luby ED, Cohen RC, Rosenbaum B, Gottlieb JS, Kelly R: Study of a new schizophrenomimetic drug: Sernyl. Arch Neurol Psychiat (1959) 81:363-369.
4. Javitt DC, Zukin SR: Recent advances in the phenycyclidine model of schizophrenia. Am J Psychiatry (1991) 148:1301-1308.
5. Carlsson M, Carlsson A: Interaction between glutamatergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease. Trends Neurosci (1990) 13:272-276. First review that emphasized the role of interaction between the dopaminergic and glutamatergic systems in schizophrenia and Parkinson's disease.
6. Danysz W, Parsons CG: Glycine and N-methyl-D-aspartate receptors: Physiological significance and possible therapeutic applications. Pharmacol Rev (1998) 50:597-664.
7. Johnson SA, Luu NT, Herbst TA, Knapp R, Lutz D, Arai A, Rogers GA, Lynch G: Synergistic interactions between ampakines and antipsychotic drugs. J Pharmacol Exp Ther (1999) 289:392-397. Solid preclinical evidence for antipsychotic-like activity of CX-516 in schizophrenia.
8. Yamada KA: Modulating excitatory synaptic neurotransmission: Potential treatment for neurological disease? Neurobiol Dis (1998) 5:67-80. Interesting overview of PMAR.
9. Arai AC, Kessler M, Rogers G, Lynch G: Effects of the potent ampakine CX614 on hippocampal and recombinant AMPA receptors: Interactions with cyclothiazide and GYKI 52466. Mol Pharmacol (2000) 58:802-813.
10. Nagarajan N, Quast C, Boxall AR, Shahid M, Rosenmund C: Mechanism and impact of allosteric AMPA receptor modulation by the ampakine CX546. Neuropharmacology (2001) 41:650-663.
11. Danysz W: CX-516 Cortex Pharmaceuticals. Curr Opin Cent Peripheral Nerv Syst Invest Drugs (1999) 1:388-396.
12. Yamada KA, Covey DF, Hsu CY, Hu R, Hu Y, He YY: The diazoxide derivative IDRA 21 enhances ischemic hippocampal neuron injury. Ann Neurol (1998) 43:664-669.
13. Yamada KA: AMPA receptor activation potentiated by the AMPA modulator 1-BCP is toxic to cultured rat hippocampal neurons. Neurosci Lett (1998) 249:119-122.
14. W Danysz: Excitatory amino acids 'Ten years later' (Part II). Selected presentations relevant for drug development, Manaus, Brazil. IDdb Meeting Report (1998), November 18-22.
15. Bahr BA, Kawasaki BT, Quach CN, Marrs C, Rogers G: Attenuation of excitotoxic damage by nanomolar levels of ampakines in long-term hippocampal slices. Abstr Soc Neurosci (1997) 23:Abs 900.9.
16. Bahr BA, Bandiske J, Brown QB, Murirathinam S, Caba E, Rudin M, Urwyler S, Sauter A, Rogers G: Survival signaling and selective neuroprotection through glutamatergic transmission. Exp Neurol (2002) 174:37-47. Interesting study on the mechanism of neuroprotective effects of CX-516.
17. Legutko B, Li X, Skolnick P: Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator. Neuropharmacology (2001) 40:1019-1027.
18. Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM: Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci (2000) 20:8-21.
19. Cortex Pharmaceuticals: Cortex Pharmaceuticals' experimental drug for schizophrenia shows statistically significant effects in cognition improvement - 'Results exceeded our expectations'. Press Release (2000), April 19.
20. Lynch G, Kessler M, Rogers G, Ambros-Ingerson J, Granger R, Schehr RS: Psychological effects of a drug that facilitates brain AMPA receptors. Int Clin Psychopharmacol (1996) 11:13-19.
21. Cortex Pharmaceuticals Inc: Cortex announces collaborative research, joint clinical research and licensing agreements. Press Release (2002), October 16.
22. Gainetdinov RR, Mohn AR, Bohn LM, Caron MG: Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proc Natl Acad Sci USA (2001) 98:11047-11054.
23. Cortex Pharmaceuticals/Organon: Cortex/Organon's schizophrenia drug to enter phase II. Press Release (2001), September 18.
24. Lockhart B, Iop F, Closier M, Lestage P: (S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide: (S18986-1) a positive modulator of AMPA receptors enhances (S)-AMPA-mediated noradrenaline release from rat hippocampal and frontal cortex slices. Eur J Pharmacol (2000) 401:145-153.
25. Lepagnol J, Lebrun C, Pilliere E, Thomas J-Y, Desos P, Cordi A, Lestagne P: Neuroexcitatory and cognition enhancing effects of S 18986 a positive allosteric modulator of glutamate AMPA receptor. Abstr Soc Neurosci (1997) 23:Abs 717.6.
26. Hede SE, Varming T, Gouliaev AH, Egebjerg J: Allosteric modulation of AMPA receptors. Abstr Soc Neurosci (2000) 26:Abs 339.5.
27. Baumbarger PJ, Muhlhauser M, Zhai J, Yang CR, Nisenbaum ES: Positive modulation of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator. J Pharmacol Exp Ther (2001) 298:86-102.
28. Vandergriff J, Huff K, Bond A, Lodge D: Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo. Neuropharmacology (2001) 40:1003-1009. Comparison of in vivo and in vitro effects in relation to dose/concentration.
29. Li X, Tizzano JP, Griffey K, Clay M, Lindstrom T, Skolnick P: Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology (2001) 40:1028-1033. Paper showing specific antidepressive-like activity of PMAR in two rodent models.
30. Zivkovic I, Thompson DM, Bertolino M, Uzunov D, DiBella M, Costa E, Guidotti A: 7-Chloro-3-methyl-3-4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA 21): A benzothiadiazine derivative that enhances cognition by attenuating DL-α-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization. J Pharmacol Exp Ther (1995) 272:300-309.
31. Kerwin R, Patel S, Meldrum B: Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience (1990) 39:25-32.
32. Eastwood SL, McDonald B, Burnet PWJ, Beckwith JP, Kerwin RW, Harrison PJ: Decreased expression of mRNAs encoding non-NMDA glutamate receptors glur1 and glur2 in medial temporal lobe neurons in schizophrenia. Brain Res Mol Brain Res (1995) 29:211-223.
33. Meador-Woodruff JH, Healy DJ: Glutamate receptor expression in schizophrenic brain. Brain Res Rev (2000) 31:288-294. Comprehensive overview of glutamate receptor alterations in schizophrenia.
34. Eastwood SL, Burnet PWJ, Harrison PJ: GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia: A reverse transcriptase-polymerase chain reaction (RT-PCR) study. Brain Res Mol Brain Res (1997) 44:92-98.
35. Eastwood SL, Kerwin RW, Harrison PJ: Immunoautoradiographic evidence for a loos of α-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia. Biol Psychiatry (1997) 41:636-643.
36. Breese CR, Freedman R, Leonard SS: Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res (1995) 674: 82-90.
37. Healy DJ, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ, Meador-Woodruff JH: AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics. Neuropsychopharmacology (1998) 19:278-286.
38. Akbarian S, Smith MA, Jones EG: Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia. Brain Res (1995) 699:297-304.
39. Moghaddam B, Adams B, Verma A, Daly D: Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci (1997) 17:2921-2927.
40. Witkin JM: Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists. Life Sci (1993) 53:PL405-PL410.
41. Vanover KE: Effects of AMPA receptor antagonists on dopamine-mediated behaviors in mice. Psychopharmacology (1998) 136:123-131.
42. Wan FJ, Geyer MA, Swerdlow NR: Presynaptic dopamine-glutamate interactions in the nucleus accumbers regulate sensorimotor gating. Psychopharmacology (1995) 120:433-441.
43. Staubli U, Perez Y, Xu FB, Rogers G, Ingvar M, Stone-Elander S, Lynch G: Centrally active modulators of glutamate receptors facilitate the induction of long-term potentiation in vivo. Proc Natl Acad Sci USA (1994) 91:11158-11162.
44. Staubli U, Rogers G, Lynch G: Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci USA (1994) 91:777-781. First paper demonstrating the effect of PMAR on memory.
45. Ingvar M, Ambros-Ingerson J, Davis M, Granger R, Kessler M, Rogers GA, Schehr RS, Lynch G: Enhancement by ampakine of memory encoding in humans. Exp Neurol (1997) 146:553-559.
46. Lynch G, Granger R, Ambros-Ingerson J, Davis CM, Kessler M, Schehr R: Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp Neurol (1997) 145:89-92.
47. Kimball JR, Johnson JA, Griffey KI, Ornstein PL, Zimmerman DM, Zarrinmayeh H, Schoepp DD, Tizzano JP: The novel AMPA receptor potentiator LY392098 enhances spatial learning and memory in a water maze. Abstr Soc Neurosci (2000) 26:Abs 528.19.
48. Gates M, Ogden A, Bleakman D: Pharmacological effects of AMPA receptor potentiators LY392098 and LY404187 on rat neuronal AMPA receptors in vitro. Neuropharmacology (2001) 40:984-991.
49. Palmer LC, Hess US, Larson J, Rogers GA, Gall CM, Lynch G: Comparison of the effects of an AMPAkine with those of methamphetamine on aggregate neuronal activity in cortex versus striatum. Mol Brain Res (1997) 46:127-135.
50. Johnson SA, Luu NT: The AMPAkine CX-516 may enhance haloperidol antagonism of amphetamine hyperactivity by enhancing haloperidol-induced nucleus accumbens activity. Abstr Soc Neurosci (1997) 23:Abs 534.9.
51. Zhai Y, George CA, Nisenbaum LK: The novel of AMPA receptor potentiator, LY392098 enhances c-fos expression in limbic forebrain areas of the rat. Abstr Soc Neurosci (2000) 26:Abs 339.22.
52. Johnson SA, Larson J, Luu NT, Herbst TA, Rogers G, Lynch G: Reduction of methamphenamine hyperactivity by AMPA receptor facilitation: Positive interaction with typical and atypical antipsychotics. Pharmacologist (1997) 39:120.
53. Larson J, Quach CN, LeDuc BQ, Nguyen A, Rogers GA, Lynch G: Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats. Brain Res (1996) 738:353-256.
54. Vanover KE: Effects of AMPA receptor positive modulators on amphetamine- and dizocilpine-induced locomotion. Eur J Pharmacol (1997) 332:115-119.
55. Cortex Pharmaceuticals Inc: Cortex receives broad patent covering combination therapies with AMPAKINEs for treatment of schizophrenia. Press Release (2001), January 24.
56. Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, Johnson SA, Lynch G: A placebo-controlled pilot study of the ampakine CX-516 added to clozapine in schizophrenia. J Clin Psychopharmacol (2001) 21:484-487. Study showing clear benefits of CX-516 when administered in combination with clozapine to schizophrenics.
57. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN: AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology (2000) 54:1589-1595.
58. Cortex Pharmaceuticals Inc: Cortex reaps $0.77 million from NIMH. Press Release (2001), October 17.
59. Boehringer Ingelheim Pharma KG (Winter K, Weiser T, Blech SM, Ceci A): Novel Positive Allosteric AMPA Receptor Modulators (PAARM), Method for the Production and Use thereof as Medicaments. WO-00157045 (2001).
60. Adir & Co (Pirotte B, De Tullio P, Boverie S, Kempen I, Lestage P): Novel Benzothiadiazine Derivatives, Preparation Method and Pharmaceutical Compositions Containing Same. WO-00140210 (2001).